Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells
Ougolkov, Andrei V., Bone, Nancy D., Fernández-Zapico, Martín E. , Billadeau, Daniel D. , Ugolkov, Andrey , Kay, Neil E.

Mayo Clinic

Blood | April 26, 2007 | Volume: 110 | Issue: 2 | Pages: 735-742

10.1182/blood-2006-12-060947 | PMID 17463171 Get It

Abstract Chronic lymphocytic leukemia (CLL) is commonly defined as a disease of failed apoptosis of B cells and remains an incurable disease. The mechanism of resistance to apoptosis in CLL is complex and influenced by numerous factors, including nuclear factor κB (NFκB)-mediated expression of antiapoptotic molecules. Recent evidence indicates that glycogen synthase kinase-3β (GSK-3β) positively regulates NFκB-mediated gene transcription and cell survival. Using malignant B cells collected from patients with CLL, we find that both GSK-3β and NFκB accumulate in the nucleus of CLL B cells, and pharmacologic inhibition of GSK-3 results in decreased expression of two NFκB target genes Bcl-2 and XIAP and a subsequent increase in CLL B-cell apoptosis ex vivo. Furthermore, we observed that inhibition of GSK-3 leads to a decrease in NFκB-mediated gene transcription but does not affect the nuclear accumulation of NFκB in CLL B cells. Last, using chromatin immunoprecipitation, we show that GSK-3 inhibition abrogates NFκB binding to its target gene promoters (XIAP, Bcl-2), in part through epigenetic modification of histones. Our results establish that inhibition of GSK-3 abrogates NFκB binding to its target gene promoters through an epigenetic mechanism, enhances apoptosis in CLL B cells ex vivo and identifies GSK-3 as a potential therapeutic target in the treatment of CLL.
Human Immunodeficiency Virus Type 1 Protease Cleaves Procaspase 8 In Vivo
Nie, Zilin , Bren, Gary D., Vlahakis, Stacey R., Schimnich, Alicia Algeciras, Brenchley, Jason M. , Trushin, Sergey A., Warren, Sarah , Schnepple, David, Kovacs, Colin , Loutfy, Mona , Douek, Daniel C. , Badley, Andrew D. , Badley, Andrew D

Mayo Clinic

Journal of Virology | April 19, 2007 | Volume: 81 | Issue: 13 | Pages: 6947-6956

10.1128/jvi.02798-06 | PMID 17442709 Get It

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) infection causes apoptosis of infected CD4 T cells as well as uninfected (bystander) CD4 and CD8 T cells. It remains unknown what signals cause infected cells to die. We demonstrate that HIV-1 protease specifically cleaves procaspase 8 to create a novel fragment termed casp8p41, which independently induces apoptosis. casp8p41 is specific to HIV-1 protease-induced death but not other caspase 8-dependent death stimuli. In HIV-1-infected patients, casp8p41 is detected only in CD4 + T cells, predominantly in the CD27 + memory subset, its presence increases with increasing viral load, and it colocalizes with both infected and apoptotic cells. These data indicate that casp8p41 independently induces apoptosis and is a specific product of HIV-1 protease which may contribute to death of HIV-1-infected cells.
Endoscopic Management of Upper Tract Urothelial Carcinoma in Patients With a History of Bladder Urothelial Carcinoma
Krambeck, Amy E. , Thompson, R. Houston, Lohse, Christine M. , Patterson, David E., Segura, Joseph W., Zincke, Horst, Elliott, Daniel S. , Blute, Michael L.

Mayo Clinic

Journal of Urology | April 15, 2007 | Volume: 177 | Issue: 5 | Pages: 1721-1726

10.1016/j.juro.2007.01.006 | PMID 17437796 Get It

Confirmation of a Positive Association between Prostate Cancer Risk and a Locus at Chromosome 8q24
Suuriniemi, Miia, Agalliu, Ilir , Schaid, Daniel J. , Johanneson, Bo, McDonnell, Shannon K. , Iwasaki, Lori, Stanford, Janet L. , Ostrander, Elaine A. , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 6, 2007 | Volume: 16 | Issue: 4 | Pages: 809-814

10.1158/1055-9965.epi-06-1049 | PMID 17416775 Get It

Abstract Background: Family-based linkage studies, association studies, and studies of tumors have highlighted human chromosome 8q as a genomic region of interest for prostate cancer susceptibility loci. Recently, a locus at 8q24, characterized by both a single nucleotide polymorphism (SNP) and a microsatellite marker, was shown to be associated with prostate cancer risk in Icelandic, Swedish, and U.S. samples. Although the data were provocative, the U.S. samples were not population based, which precludes assessment of the potential contribution of this locus to prostate cancer incidence in the United States. Methods: We analyzed both markers in a population-based, case-control study of middle-aged men from King County, Washington. Results: Overall, there was a significant positive association between the A allele of the SNP rs1447295 and prostate cancer risk [odds ratio, 1.4; 95% confidence interval (95% CI), 1.1-2.0] but no significant association with the microsatellite DG8S737. However, significant associations were observed for both markers in men with high Gleason scores. Adjusting for age, first-degree family history of prostate cancer, and prostate cancer screening history, the adjusted odds ratios were 1.4 (95% CI, 1.1-1.8) for the A allele of the SNP and 1.9 (95% CI, 1.2-2.8) for the −10 allele of the microsatellite. Conclusions: These data suggest that the locus on chromosome 8q24 harbors a genetic variant associated with prostate cancer and that the microsatellite marker is a stronger risk factor for aggressive prostate cancers defined by poorly differentiated tumor morphology. (Cancer Epidemiol Biomarkers Prev 2007;16(4):809–14)
Two Common Chromosome 8q24 Variants Are Associated with Increased Risk for Prostate Cancer
McDonnell, Shannon K. , Slusser, Joshua P. , Hebbring, Scott J. , Cunningham, Julie M. , Jacobsen, Steven J. , Cerhan, James R. , Blute, Michael L., Schaid, Daniel J. , Thibodeau, Stephen N. , Wang, Liang , Cerhan, James R , McDonnell, Shannon K

Mayo Clinic

Cancer Research | April 5, 2007 | Volume: 67 | Issue: 7 | Pages: 2944-2950

10.1158/0008-5472.can-06-3186 | PMID 17409399 Get It

Abstract Two variants (rs1447295/DG8S737) of chromosome 8q24 were recently reported to be associated with increased risk of prostate cancer (PC). To confirm this finding, we genotyped and compared the frequencies of these polymorphisms among 1,121 Caucasian men with PC (435 men with familial PC, 491 men with sporadic PC, and 195 men with aggressive PC) to 545 population-based controls. For the single nucleotide polymorphism marker rs1447295, frequencies of the minor allele (A) were 10.3% in controls, 11.9% in sporadic cases, 16.7% in familial cases, and 17.2% in aggressive cases. Compared with controls, the A allele was significantly more common in both familial PC [odds ratios (OR), 1.93; 95% confidence intervals (95% CI), 1.37–2.72; P = 0.0004] and aggressive PC (OR, 1.87; 95% CI, 1.28–2.74; P = 0.0005) but not for sporadic PC (OR, 1.16; 95% CI, 0.85–1.58; P = 0.25). Although the A allele was more frequent in aggressive PC cases when compared with controls, the allele frequencies were similar among cases with high- and low-grade PC (Gleason grades <7 and ≥7, respectively). For the microsatellite marker DG8S737, the −8 allele was significantly more frequent in familial PC (OR, 1.68; 95% CI, 1.09–2.60; P = 0.031), whereas the −10 allele was more frequent in aggressive PC (OR, 2.85; 95% CI, 1.52–5.36; P = 0.0004). Haplotype analysis showed significant differences in haplotype frequencies between the familial PC (P = 0.006) and aggressive PC (P = 0.005) cases versus controls. The −8/A haplotype showed the strongest association with familial PC (P = 0.008), whereas the −10/A haplotype was most strongly associated with aggressive PC (P = 0.00005). These results further confirm the importance of these two polymorphic variants (rs1447295 and DG8S737) as risk factors for PC. However, the mechanism explaining this increased risk has not yet been established. [Cancer Res 2007;67(7):2944–50]
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
Tallman, Martin S. , Dewald, Gordon W., Gandham, Sharavi, Logan, Brent R. , Litzow, Mark R. , Mehta, Jayesh, Pedersen, Tanya L., Pérez, Waleska S., Rowe, Jacob M. , Wetzler, Meir , Weisdorf, Daniel J. , Keating, Armand , Lazarus, Hillard M. , Weisdorf, Dan

Mayo Clinic

Blood | March 21, 2007 | Volume: 110 | Issue: 1 | Pages: 409-417

10.1182/blood-2006-10-043299 | PMID 17374741 Get It

We compared the treatment-related mortality, relapse rate, disease-free survival (DFS), and overall survival (OS) by cytogenetic risk group of 261 patients with acute myeloid leukemia in first complete remission (CR1) and 299 patients in CR2 in undergoing matched unrelated donor hematopoietic stem cell transplantation (HSCT). For patients in first CR, the DFS and OS at 5 years were similar for the favorable, intermediate, and unfavorable risk groups at 29% (95% confidence interval [CI], 8%-56%) and 30% (22%-38%); 27% (19%-39%) and 29% (8%-56%); and 30% (95% CI, 22%-38%) and 30% (95% CI, 20%-41%), respectively. For patients in second CR, the DFS and OS at 5 years were 42% (95% CI, 33%-52%) and 35% (95% CI, 28%-43%); 38% (95% CI, 23%-54%) and 45% (95% CI, 35%-55%); and 37% (95% CI, 30%-45%) and 36% (95% CI, 21%-53%), respectively. Cytogenetics had little influence on the overall outcome for patients in first CR. In second CR, outcome was modestly, but not significantly, better for patients with favorable cytogenetics. The graft-versus-leukemia effect appeared effective, even in patients with unfavorable cytogenetics. However, treatment-related mortality was high. Matched unrelated donor HSCT should be considered for all patients with unfavorable cytogenetics who lack a suitable HLA-matched sibling donor.
Association of High Tidal Volume with Postpneumonectomy Failure
Keegan, Mark T. , Brown, Daniel R. , Hubmayr, Rolf D., Gajic, Ognjen, Pérez, Evans R. Fernández

Mayo Clinic

Anesthesiology | March 19, 2007 | Volume: 106 | Issue: 4 | Pages: 876-876

10.1097/01.anes.0000264783.69113.ff Get It

Seasonal Variation in Human Illumination Exposure at Two Different Latitudes
Cole, Roger J. , Wisbey, Joyce, Mason, William J., Gruen, William, Hauri, Peter, Juárez, Silvia, Kripke, Daniel F.

Mayo Clinic

Journal of Biological Rhythms | March 11, 2007 | Volume: 10 | Issue: 4 | Pages: 324-334

10.1177/074873049501000406 | PMID 8639941 Get It

The authors measured ambient illumination exposure in healthy volun teers in San Diego, California (latitude 32° 43' N, n = 30), and Rochester, Minne sota (latitude 44° 1'N, n = 24), during each of the four quarters of the year, which were centered on the solstices and equinoxes. Subjects wore photosensors on their wrists and lapels (or foreheads while in bed) 24 h per day for an average of 5-6 days per quarter. The maximum of the two illumination readings was stored each minute. Annual average time spent per day in outdoor illumination (≥ 1000 lux) was significantly higher in San Diego than it was in Rochester (p <.04). Daily durations of illumination at or exceeding thresholds of 1,10,100,1000, and 10,000 lux were highly seasonal in the sample as a whole (p < .01 at 1 lux, p < .0001 at other thresholds). Seasonal variation in outdoor illumination was far more pronounced in Rochester than it was in San Diego (interaction p < .001) but remained significant in San Diego ( p ≤ .03). Seasonal variation in indoor illumi nation was generally similar in the two cities. The median Rochester subject experienced illumination ≥ 1000 lux for 2 h 23 min per day during summer and 23 min per day during winter. The corresponding times in San Diego were 2 h 10 min and 1 h 20 min. Neither age nor gender predicted illumination duration at any level. Both season and geographic location strongly influenced human illumination exposure, and behavior (choice of indoor vs. outdoor environment) was the most important mediating factor.
The Five-Factor Model of Personality: Findings in Males with Spinal Cord Injury
Rohe, Daniel E. , Krause, James S.

Mayo Clinic

Assessment | March 10, 2007 | Volume: 6 | Issue: 3 | Pages: 203-213

10.1177/107319119900600301 | PMID 10445958 Get It

The purpose of this study was to identify common personality traits in males with traumatic spinal cord injury (SCI). One hundred and five participants with SCI completed the NEO Personality Inventory (NEO-PI). The participants averaged 41.1 years of age and 17.9 years since injury onset. Compared with the NEO-PI normative sample, the SCI sample scored significantly lower on the Conscientiousness factor and the Activity and Assertiveness facet scales. They scored significantly higher on the Excitement-Seeking scale. These results suggest that males with SCI are less determined, have lower energy levels, are socially retiring, and that they tend to seek stimulation. These findings may reflect the contribution of both preinjury personality traits and adaptation to the limitations imposed by SCI.